tradmap

RLAY Relay Therapeutics, Inc.

$15.89 +2.15%

Healthcare · Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc. (RLAY) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $3.0 billion. Shares last traded at $15.89, 8.8% below their 52-week high. Over the past year the stock is up 422.9%. Net profit margin is -1800.6%, below the peer median of 6.3%. Revenue grew 53.4% year over year.

Market Cap
$3.0B
Shares Out
191.6M
EPS (TTM)
$-3.04
P/E Ratio
P/S Ratio
198.32
P/B Ratio
4.74
Dividend / Share
Dividend Yield
52-Week High
$17.42
52-Week Low
$2.99
Volume
281,888
Avg Vol (3m)
227,909.556

Performance

1W
+11.78%
1M
+31.85%
3M
+58.95%
6M
+87.00%
YTD
+94.08%
1Y
+422.86%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
63.97
SMA (50)
$14.17
SMA (200)
$9.31
Price vs SMA50
+12.15%
Price vs SMA200
+70.66%
ATR (14)
$1.32

Financials

Revenue
$15M
Net Income
$-276M
Gross Margin
Operating Margin
-1971.6%
Net Margin
-1800.6%
Return on Equity
-43.1%
Return on Assets
-39.5%
Current Ratio
22.13
Debt / Equity
0.09
Revenue Growth (YoY)
+53.4%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.41 2026-05-05
FY 2025 $-1.61 2026-02-26
Q3 2025 $-1.30 2025-11-06
Q2 2025 $-0.87 2025-08-07
Q1 2026 $-0.46 2026-05-05
FY 2025 $-2.36 2026-02-26

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

RLAY vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
198.32 / 5.21 med
+3704% premium
Net margin vs peers
-1800.6% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.